Kelly Valla, PharmD, BCOP

An oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.

Tazemetostat use only requires dosing modifications in a small percentage of patients, according to an oncology pharmacist.

Adverse effects in patients taking tazemetostat were manageable, with most patients reporting low-grade fatigue, pain, and nausea.

An oncology pharmacist details the unique mechanism of active of tazemetostat in the treatment of follicular lymphoma.

With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists. 

In this article, we describe the considerations for the use of BTK inhibitors in lymphoid malignancies from the perspective of an oncology pharmacist.

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.